PubMed · 2013 · 16 citations · 13 references
Life SciencesOncologyPharmacologyCell SignalingMolecular Cell BiologySignal TransductionCancer Cell SignalingMtor Inhibitor TherapyNotch SignalingOncogenic Signaling PathwaysProtein Kinase CascadesSignal Transduction In CancerCell Growth RegulationCrosstalkMammalian Target Of Rapamycin SignalingMtor Complex 1 RegulationMtor InhibitionMtor SignalingNotch Signaling ActivationTargeted Molecular Therapy
AIM: PP242 is a compound which inhibits both mammalian target of rapamycin complex-1 (mTORC1) and mTORC2. We examined the effects of PP242 and rapamycin on mTOR signalling and evaluated potential crosstalk with the NOTCH signalling in eight leukemia cell lines. MATERIALS AND METHODS: We examined the effects of treatment with these inhibitors on cell growth and protein expression. RESULTS: PP242 suppressed growth more potently than did rapamycin. In two cell lines poorly sensitive to PP242, PP242 failed to inhibit v-akt murine thymoma viral oncogene homolog (AKT) phosphorylation. Suppression of mTOR phosphorylation was weaker in myeloid cell lines. Rapamycin induced eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) hyperphosphorylation in three cell lines. Phosphorylation of both isoforms (p70 and p85) of S6 kinase (S6K) was suppressed in three cell lines; only p70 was suppressed in the others. NOTCH1 expression and activation were up-regulated by PP242 in one cell line but down-regulated in another. CONCLUSION: PP242 is a candidate for molecular-targeted leukemia therapy, although its effects must be evaluated on a case-by-case basis. Crosstalk was found between the mTOR and NOTCH signalling pathways.
13
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero, Maria Luisa Sulis, Maria S. Cortina et al. · Nature Medicine · 2007 · 872 citations · Full text
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes, Jose J. Limon, Lomon So et al. · Nature Medicine · 2010 · 338 citations · Full text
Medicine, Oncology, Pharmacology +14